Allspring Global Investments Holdings LLC Grows Stake in Edwards Lifesciences Corporation $EW

Allspring Global Investments Holdings LLC grew its position in Edwards Lifesciences Corporation (NYSE:EW) by 221.1% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,060,891 shares of the medical research company’s stock after buying an additional 1,419,022 shares during the quarter. Allspring Global Investments Holdings LLC’s holdings in Edwards Lifesciences were worth $167,468,000 at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in EW. MV Capital Management Inc. purchased a new stake in Edwards Lifesciences during the 4th quarter worth about $26,000. Hanson & Doremus Investment Management purchased a new stake in shares of Edwards Lifesciences during the first quarter worth about $25,000. Kemnay Advisory Services Inc. acquired a new position in shares of Edwards Lifesciences in the fourth quarter valued at approximately $27,000. JPL Wealth Management LLC acquired a new stake in Edwards Lifesciences during the third quarter worth approximately $25,000. Finally, Hilton Head Capital Partners LLC acquired a new position in Edwards Lifesciences in the 4th quarter valued at $28,000. 79.46% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 1,019 shares of Edwards Lifesciences stock in a transaction that occurred on Friday, May 1st. The stock was sold at an average price of $83.01, for a total value of $84,587.19. Following the completion of the transaction, the vice president directly owned 33,934 shares in the company, valued at $2,816,861.34. The trade was a 2.92% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Andrew M. Dahl sold 568 shares of the stock in a transaction on Friday, May 29th. The stock was sold at an average price of $86.08, for a total value of $48,893.44. Following the completion of the sale, the senior vice president directly owned 15,334 shares in the company, valued at $1,319,950.72. This represents a 3.57% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 45,577 shares of company stock valued at $3,855,527 over the last quarter. Insiders own 0.31% of the company’s stock.

Edwards Lifesciences Price Performance

Shares of NYSE EW opened at $87.92 on Friday. Edwards Lifesciences Corporation has a fifty-two week low of $72.30 and a fifty-two week high of $96.29. The company has a quick ratio of 3.63, a current ratio of 4.42 and a debt-to-equity ratio of 0.06. The firm has a market cap of $50.63 billion, a PE ratio of 46.77, a price-to-earnings-growth ratio of 2.19 and a beta of 0.86. The business has a 50 day moving average price of $87.22 and a two-hundred day moving average price of $83.93.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Thursday, April 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.73 by $0.05. Edwards Lifesciences had a net margin of 17.39% and a return on equity of 15.19%. The business had revenue of $1.65 billion for the quarter, compared to analyst estimates of $1.60 billion. During the same quarter in the prior year, the business posted $0.64 EPS. The company’s revenue for the quarter was up 16.7% on a year-over-year basis. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. Sell-side analysts expect that Edwards Lifesciences Corporation will post 3 earnings per share for the current fiscal year.

Analyst Ratings Changes

EW has been the subject of several analyst reports. Evercore reiterated an “outperform” rating and issued a $100.00 target price on shares of Edwards Lifesciences in a research note on Monday, July 6th. Canaccord Genuity Group set a $85.00 price objective on shares of Edwards Lifesciences and gave the company a “hold” rating in a research note on Friday, April 24th. Wall Street Zen cut shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a research report on Saturday, July 4th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Edwards Lifesciences in a research report on Monday, April 20th. Finally, Truist Financial lifted their price target on shares of Edwards Lifesciences from $90.00 to $95.00 and gave the company a “hold” rating in a report on Thursday. Two research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and seven have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $98.95.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.